Skip to Main Content
TABLE 2

Clinical Outcomes of Children with MRSA Bacteremia

Entire Cohort
(N = 232)Treated With Vancomycin and With Steady-State Trough
(n = 174)Treated With Vancomycin but No Steady-State Trough
(n = 31)Not Treated With Vancomycin
(n = 27)
Treatment failure 72 (31.0) 60 (34.5) 9 (29.0) 3 (11.1) 
Attributable mortality within 30 d 5 (2.2) 2 (1.2) 3 (9.7) 0 (0) 
Duration of bacteremia, median, d (IQR) 2 (1–4) 2 (1–4) 2 (1–3) 1 (1–3) 
 Persistent bacteremia >3 d 64 (27.6) 54 (31.0) 7 (22.6) 3 (11.1) 
 Persistent bacteremia >5 d 30 (12.9) 26 (14.9) 3 (9.7) 1 (3.7) 
 Persistent bacteremia >7 d 24 (10.3) 16 (9.2) 2 (6.5) 1 (3.7) 
Recurrence of bacteremia 7 (3.0) 6 (3.5) 1 (3.2) 0 (0) 
Attributable readmission within 30 d 11 (4.7) 10 (5.7) 1 (3.2) 0 (0) 
Duration of fever, median, d (IQR) 3 (2–7) 3.5 (2–8) 3 (2–6) 4 (1–6) 
Any sequelae 54 (23.3) 43 (24.7) 9 (29.0) 2 (7.4) 
 Progression of infection 17 (7.3) 14 (8.1) 1 (3.2) 2 (7.4) 
 Septic emboli/thrombus 17 (7.4) 15 (8.6) 2 (6.5) 0 (0) 
 Metastatic focus of infection 16 (6.9) 12 (6.9) 5 (16.1) 0 (0) 
 Othera 3 (1.3) 3 (1.7) 2 (6.5) 2 (7.4) 
Entire Cohort
(N = 232)Treated With Vancomycin and With Steady-State Trough
(n = 174)Treated With Vancomycin but No Steady-State Trough
(n = 31)Not Treated With Vancomycin
(n = 27)
Treatment failure 72 (31.0) 60 (34.5) 9 (29.0) 3 (11.1) 
Attributable mortality within 30 d 5 (2.2) 2 (1.2) 3 (9.7) 0 (0) 
Duration of bacteremia, median, d (IQR) 2 (1–4) 2 (1–4) 2 (1–3) 1 (1–3) 
 Persistent bacteremia >3 d 64 (27.6) 54 (31.0) 7 (22.6) 3 (11.1) 
 Persistent bacteremia >5 d 30 (12.9) 26 (14.9) 3 (9.7) 1 (3.7) 
 Persistent bacteremia >7 d 24 (10.3) 16 (9.2) 2 (6.5) 1 (3.7) 
Recurrence of bacteremia 7 (3.0) 6 (3.5) 1 (3.2) 0 (0) 
Attributable readmission within 30 d 11 (4.7) 10 (5.7) 1 (3.2) 0 (0) 
Duration of fever, median, d (IQR) 3 (2–7) 3.5 (2–8) 3 (2–6) 4 (1–6) 
Any sequelae 54 (23.3) 43 (24.7) 9 (29.0) 2 (7.4) 
 Progression of infection 17 (7.3) 14 (8.1) 1 (3.2) 2 (7.4) 
 Septic emboli/thrombus 17 (7.4) 15 (8.6) 2 (6.5) 0 (0) 
 Metastatic focus of infection 16 (6.9) 12 (6.9) 5 (16.1) 0 (0) 
 Othera 3 (1.3) 3 (1.7) 2 (6.5) 2 (7.4) 

Data are presented as n (%) unless otherwise noted.

a

Other sequelae include development of stroke, need for amputation, or need for extracorporeal membranous oxygenation.

Close Modal

or Create an Account

Close Modal
Close Modal